|
Biotech Holdings readies first production run of Sucanon Diabetes drug Wednesday, April 14, 2004 09:01 ET VANCOUVER, Apr 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages. There are 60 tablets in each one-month treatment regimen," Mr. Rieveley said. "A portion of this initial production is being allocated for marketing purposes, including distribution through symposia for introducing Sucanon to doctors, pharmacists and clinics in Mexico. The bulk of the first production of tablets however will be shipped for sale by our marketers in Mexico and the start of Sucanon revenues for Biotech," Mr. Rieveley said. World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is one of the largest markets in the world for Type II Diabetes drugs. Biotech Holdings` Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients` ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 18 million people in North America, over 30 million in Latin America and nearly 200 million worldwide. Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil. If you would you would like to be added to Biotech Holdings` email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp Biotech Holdings Ltd.`s head office is in Richmond, British Columbia. Biotech Holdings` shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com. SOURCE Biotech Holdings Ltd. CONTACT: Austin Rand at Biotech Holdings Ltd., 1-888-216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com. (BIO. BIOHF) http://www.prnewswire.com Copyright (C) 2004 PR Newswire. All rights reserved. -0- KEYWORD: British Columbia INDUSTRY KEYWORD: MTC OTC STOCK SYMBOLS: [(bio.)] [(biohf)] JS200 |
|
| aus der Diskussion: | Biotech Holdings Ltd (OTCBB:BIOHF) die neue Perle in Sachen DIABETIS |
| Autor (Datum des Eintrages): | js200 (14.04.04 17:15:48) |
| Beitrag: | 14 von 42 (ID:12743203) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |